Cyclo phosphamide in high doses compared with combined cyclo phosphamide methotrexate 5 fluoro uracil and hydroxy urea in the treatment of non oat cell carcinoma of the lung study of phase 3

Rossi A.P.

Mediterranee Medicale 252: 73-74, 77-79


ISSN/ISBN: 0302-9263
Accession: 005079549

Download citation:  

Article/Abstract emailed within 1 workday
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Two treatment plans were used in 58 patients suffering from non-oat cell carcinoma of the lung (23 with epidermoid carcinoma of the lung (23 with epidermoid carcinoma, 22 with adenocarcinoma and 3 with large-cell anaplastic carcinoma), 1 group receiving cyclophosphamide (CTX) and the other receiving CMFH. [cyclophosphamide, methotrexate, 5-fluorouracil, hydroxyurea]. Two partial remissions (RP) were recorded, 1 for each regime (3%); 59% of patients treated with CTX and 48.5% of patients treated with CMF showed no change in condition. CMFH proved more effective than CTX only as to subjective remissions. Patients treated with CTX showed an average survival of 24 wk while those treated with CMFH survived for 26 wk (difference not statistically significant). Survival with CMFH was better for cases of epidermoid carcinoma (average 32 wk) than for adenocarcinoma or large-cell anaplastic carcinoma.